Just the true innovation！

Unlike the companies that have been touted, Heartseed is definitely the real candidate for the treatment of heart failure with iPS cell-derived cardiomyocytes, and we have analysed the successful results of the company's P1 clinical trial that convinced us of this. The side effect of concern, arrhythmia, has also been cleared.
https://miyata-bio.net/column/0000351/